Gastrin I (human): Advancing Intestinal Organoid and CCK2 Receptor Signaling Research

Introduction

Gastrin I (human) is a critical endogenous peptide hormone that orchestrates gastric acid secretion through precise receptor-mediated mechanisms. As research moves beyond classic models to embrace sophisticated in vitro systems such as human pluripotent stem cell-derived intestinal organoids, the utility of Gastrin I (human) as a research tool is expanding. This article explores the nuanced applications of the human Gastrin I peptide in dissecting gastric acid secretion pathways, CCK2 receptor signaling, and the physiological relevance of these processes in contemporary gastrointestinal models.

Gastrin I (human) and Its Mechanistic Role in Gastric Acid Secretion Regulation

Gastrin I (human), with a molecular weight of 2098.22 Da and CAS number 10047-33-3, is a member of the gastrin peptide family renowned for its regulatory influence over gastric acid secretion. Upon binding to specific CCK2 (cholecystokinin-2) receptors on parietal cells, Gastrin I acts as a potent agonist, initiating a cascade of intracellular events that ultimately activate the H⁺/K⁺-ATPase proton pump. This receptor-mediated signal transduction amplifies acid release, thereby regulating the stomach’s luminal environment and influencing downstream digestive processes. The peptide’s high purity (≥98%, HPLC and MS-verified) and chemical stability (supplied lyophilized, soluble in DMSO) make it exceptionally suited for in vitro studies requiring robust and reproducible results.

Emerging Applications in Intestinal Organoid Models

The landscape of gastrointestinal research has been transformed by advances in organoid technology. Traditional models—including animal systems and cancer-derived cell lines like Caco-2—have demonstrated inherent limitations, such as species differences and altered expression of key drug-metabolizing enzymes. Human induced pluripotent stem cell (hiPSC)-derived intestinal organoids now offer a physiologically relevant platform for probing intestinal function, pharmacokinetics, and disease mechanisms.

Recent work by Saito et al. (European Journal of Cell Biology, 2025) has established protocols for generating hiPSC-derived intestinal organoids (iPSC-IOs) with robust self-renewal and differentiation potential. These organoids recapitulate the complex cellular composition of the human small intestine, including enterocytes, goblet cells, enteroendocrine cells, and Paneth cells. Notably, iPSC-IO-derived intestinal epithelial cells (IECs) exhibit functional transporter and cytochrome P450 enzyme activity, making them highly suitable for pharmacokinetic and physiological investigations.

In this context, Gastrin I (human) serves as a crucial tool for interrogating the gastric acid secretion pathway and CCK2 receptor signaling within organoid-derived systems. By applying Gastrin I to these models, researchers can investigate the direct effects of peptide-receptor engagement on intracellular signaling, proton pump activation, and acid secretion—bridging the gap between classic mechanistic studies and cutting-edge organoid platforms.

Dissecting CCK2 Receptor Signaling and Receptor-Mediated Signal Transduction

The CCK2 receptor (also known as the gastrin/CCK-B receptor) is a G protein-coupled receptor (GPCR) predominantly expressed in gastric parietal and enterochromaffin-like cells. Agonist binding by Gastrin I initiates a signaling cascade involving phospholipase C activation, inositol trisphosphate (IP₃) production, and subsequent calcium mobilization. These events modulate the activity of the gastric proton pump, culminating in regulated acid secretion.

Utilizing Gastrin I (human) as a defined CCK2 receptor agonist in in vitro systems enables high-resolution studies of receptor pharmacodynamics, downstream effector activation, and feedback regulatory mechanisms. In organoid-derived IECs, such approaches offer a window into the physiological relevance of CCK2 receptor signaling in a more native-like cellular context, compared to immortalized cell lines or animal models.

Gastrin I (human) in Gastrointestinal Disorder Research

Dysregulation of gastric acid secretion and CCK2 receptor signaling is implicated in various gastrointestinal disorders, including peptic ulcer disease, Zollinger-Ellison syndrome, and some forms of gastric cancer. By leveraging the human Gastrin I peptide in advanced models—such as hiPSC-IO-derived IECs—researchers can dissect the molecular underpinnings of disease-associated phenotypes, test candidate therapeutics targeting the CCK2 pathway, and develop assays for drug screening and biomarker discovery.

The specificity, solubility profile (insoluble in water and ethanol, soluble in DMSO), and QC-validated purity of Gastrin I (human) make it an ideal candidate for such applications, particularly where experimental rigor and reproducibility are paramount.

Technical Considerations and Best Practices in In Vitro Gastrin I Applications

When designing experiments involving Gastrin I (human), several technical factors must be considered:

• Solubilization: Gastrin I is best dissolved in DMSO at concentrations ≥21 mg/mL. Avoid prolonged storage of solutions; prepare fresh aliquots as needed.
• Storage: Maintain the lyophilized peptide desiccated at -20°C for optimal stability.
• Purity Assurance: Use only highly purified preparations (≥98%, HPLC and MS-confirmed) to minimize confounding effects from peptide impurities.
• Model Selection: For translational relevance, consider using hiPSC-derived intestinal organoids or IECs as model systems to study receptor-mediated signal transduction, as recommended by Saito et al. (2025).

These technical guidelines ensure reproducible outcomes in studies ranging from basic receptor pharmacology to complex gastrointestinal physiology research.

Integrating Gastrin I (human) into Next-Generation Gastric Acid Secretion Pathway Research

Beyond its classical use in stimulating acid secretion in isolated stomach preparations, Gastrin I (human) now finds application in the context of organoid-based models that better recapitulate the human gastrointestinal environment. This evolution is catalyzed by the need for more predictive in vitro systems for drug development, disease modeling, and personalized medicine.

For example, by applying Gastrin I to hiPSC-IO-derived IECs, researchers can:

• Map the dynamics of CCK2 receptor signaling in a controlled, human-relevant context.
• Assess the downstream effects on proton pump activation and acid secretion.
• Investigate interactions with other signaling pathways implicated in gastrointestinal physiology and pathology.
• Screen novel compounds for modulatory effects on the gastric acid secretion pathway.

Such strategies advance our understanding of fundamental mechanisms while supporting translational goals in gastrointestinal disorder research.

Key Findings from Recent Organoid Research: Implications for Gastrin I Studies

The protocol developed by Saito et al. (2025) offers a breakthrough in the derivation and maintenance of human intestinal organoids with mature, functional cell types. These organoids provide a robust platform to evaluate not only drug metabolism and transporter function but also the physiological responses to hormonal regulators like Gastrin I (human). By incorporating this peptide into organoid and IEC studies, researchers can:

• Simulate and quantify gastric acid secretion dynamics in vitro.
• Dissect the contribution of CCK2 receptor signaling to epithelial cell function.
• Model disease-associated alterations in gastric and intestinal physiology.
• Bridge the gap between mechanistic studies and clinical relevance.

Importantly, these advances highlight the unique power of integrating defined peptide agonists, such as Gastrin I, into next-generation platforms for gastrointestinal research.

Conclusion

Gastrin I (human) stands at the nexus of classical gastric acid secretion research and the emerging field of intestinal organoid modeling. As a high-purity, receptor-specific peptide, it enables detailed interrogation of CCK2 receptor signaling, proton pump activation, and receptor-mediated signal transduction in both established and next-generation in vitro systems. The fusion of this tool with hiPSC-derived organoid models, as exemplified by the work of Saito et al. (2025), opens new avenues for gastrointestinal physiology studies, pharmacokinetic assessments, and gastrointestinal disorder research.

Unlike prior articles such as Gastrin I (human) in CCK2 Signaling: Advanced Insights for Receptor Pathways, which primarily review the peptide’s role within canonical receptor signaling frameworks, this article uniquely emphasizes the integration of Gastrin I into organoid-based platforms and translational research contexts. By focusing on the intersection of peptide pharmacology and advanced human-relevant in vitro models, this work extends the field and provides practical guidance for leveraging Gastrin I (human) in the era of organoid-driven discovery.